Background Literature:1-(3,4-methylenedioxybenzyl)-piperazine (MDBP), a piperazine designer drug/ novel and new psychoactive substance, has been misused extensively over the last several years. MDBP screening and measurement methods are now well-documented. However, relatively few in silico, in vitro, and in vivo investigations have investigated the pharmacodynamic characteristics and dopaminergic neuropharmacological profile of MDBP. Specific Aim: To establish the pharmacodynamic properties and in vitro dopaminergic neuropharmacological mechanisms of MDBP. Materials and Methods: N27 dopaminergic neuronal cells were used in the current research to explicate the effects of MDBP on dopaminergic neuronal viability, ROS and RNS generation, the content of nitrite, lipid peroxide, glutathione, NADH, and the activities of enzymes such as cyclooxygenase, NADH dehydrogenase, interleukin converting enzyme, caspases (3,8,9), monoamine oxidase and tyrosine hydroxylase. These biochemical parameters allow the effect of MDBP on oxidative stress, mitochondrial function, inflammation, and apoptosis. Results and Discussion: MDBP did not affect the dopaminergic neuronal viability. MDBP showed no significant influence on tyrosine hydroxylase activity. However, it significantly inhibited the activity of monoamine oxidase. Likewise, MDBP exhibited no negative impact on the mitochondrial function and had no significant impact on the markers of apoptosis and inflammation. Due to the preceding factors, MDBP might have no or minimal monoaminergic neurotoxic consequences. With more reliable data from in vivo research, MDBP might be a therapeutic or preventative treatment for a wide range of human and animal disorders. If these novel and new psychoactive substances can increase the dopaminergic neurotransmission without any significant neurotoxicity, they can be used to treat Parkinson’s disease and Depression.